Infect Chemother.  2015 Mar;47(1):1-11. 10.3947/ic.2015.47.1.1.

Resurgence of Mumps in Korea

• Park SH

• KMID: 1909518
• DOI: http://doi.org/10.3947/ic.2015.47.1.1

Abstract

Routine vaccination against mumps has markedly reduced its incidence. However, the incidence of mumps continuously has increased since 2007. In 2013, a large mumps epidemic occurred in Korea, and this epidemic is still an ongoing problem. This epidemic occurred primarily in school settings and affected vaccinated adolescents, predominantly male students. The recent resurgence of mumps is caused by multiple factors: suboptimal effectiveness of the current mumps vaccines, use of the Rubini strain vaccine, waning immunity in the absence of natural boosting due to the marked reduction in the mumps incidence, genotype mismatch between the vaccine and circulating mumps virus strains, and environmental conditions that foster intense exposures. Containment of mumps outbreaks is challenging because the sensitivity of diagnostic tests is low among vaccinees and control measures are less efficient because of the inherent nature of the mumps virus. Despite the suboptimal vaccine effectiveness in outbreak settings, maintaining the high vaccine coverage is an important strategy to prevent mumps outbreaks, given that the routine use of mumps vaccines has substantially reduced the incidence of mumps and its complications as compared with that in the pre-vaccine era. In order to control the current mumps epidemic and prevent further outbreaks, we need to better understand the dynamics of mumps among vaccinated populations and the changing epidemiology in Korea. Concerted efforts should be made to systematically monitor the immunization status of the Korean population and to improve diagnosis efficiency. Furthermore, more effective mumps vaccines need to be developed in the future.

Keyword

Mumps; Mumps vaccine; Adolescents; Male; Incidence; Disease outbreaks; Genotype; Republic of Korea

MeSH Terms

Adolescent
Containment of Biohazards
Diagnosis
Diagnostic Tests, Routine
Disease Outbreaks
Epidemiology
Genotype
Humans
Immunization
Incidence
Korea
Male
Mumps Vaccine
Mumps virus
Mumps*
Republic of Korea
Vaccination
Vaccines
Mumps Vaccine
Vaccines

Figure

• 

  Figure 1 Number of reported mumps cases and the annual incidence of mumps in Korea since 1955, and the mumps vaccine strains used in Korea. MMR, measles-mumps-rubella; MR, measles-rubella; NIP, National Immunization Program; mo, months; yr, years.

• 

  Figure 2 Number of reported mumps cases in Korea during 2013-2014 by age (A) compared with previous years (2007-2012) and by gender (B).

• 

  Figure 3 Changes in proportions of reported mumps cases in Korea by age between 2001 and 2014.

• 

  Figure 4 Cumulative number of reported mumps cases in Korea between 2010 and 2014, by region.

• 

  Figure 5 Monthly distribution of reported mumps cases and school terms in Korea between 2010 and 2014.

• 

  Figure 6 Changes in critical vaccination coverage according to vaccine effectiveness and the basic reproductive number. VE, vaccine effectiveness.

Reference

1. Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008; 371:932–944.

2. Choi KM. Reemergence of mumps. Korean J Pediatr. 2010; 53:623–628.

3. Lee SG. Korea national immunization survey. Osong, Korea: KCDC;2012.

4. Korea Centers for Disease Control and Prevention (KCDC). Infectious diseases surveillance yearbook, 2013. Osong, Korea: KCDC;2013.

5. Anis E, Grotto I, Moerman L, Warshavsky B, Slater PE, Lev B. Mumps outbreak in Israel's highly vaccinated society: are two doses enough? Epidemiol Infect. 2012; 140:439–446.

6. Whelan J, van Binnendijk R, Greenland K, Fanoy E, Khargi M, Yap K, Boot H, Veltman N, Swaan C, van der Bij A, de Melker H, Hahné S. Ongoing mumps outbreak in a student population with high vaccination coverage, Netherlands, 2010. Euro Surveill. 2010; 15:pii: 19554.

7. St-Martin G, Knudsen LK, Engsig FN, Panum I, Andersen PH, Rønn J, Fonager J, Fischer TK. Mumps resurgence in Denmark. J Clin Virol. 2014; 61:435–438.

8. Braeye T, Linina I, De Roy R, Hutse V, Wauters M, Cox P, Mak R. Mumps increase in Flanders, Belgium, 2012-2013: results from temporary mandatory notification and a cohort study among university students. Vaccine. 2014; 32:4393–4398.

9. Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM, Hunt K, Finley CG, Leschinsky DP, O'Keefe AL, Clayton J, Kightlinger LK, Dietle EG, Berg J, Kenyon CL, Goldstein ST, Stokley SK, Redd SB, Rota PA, Rota J, Bi D, Roush SW, Bridges CB, Santibanez TA, Parashar U, Bellini WJ, Seward JF. Recent resurgence of mumps in the United States. N Engl J Med. 2008; 358:1580–1589.

10. Centers for Disease Control and Prevention (CDC). Mumps epidemic-United kingdom, 2004-2005. MMWR Morb Mortal Wkly Rep. 2006; 55:173–175.

11. Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ. 2005; 330:1132–1135.

12. Kang IG. Serological survey on mumps virus in Korea (1970). Korean J Public Health. 1970; 7:713–718.

13. Baeg WH. A study on the investigation of the hemagglutination inhibition antibody titers against mumps virus in Seoul. Korean J Public Health. 1975; 12:69–73.

14. Shin YO, Baeg WH, Paik SB. Serological survey on mumps virus. Rep Natl Ins Health. 1977; 14:117–121.

15. Kim JS, Choi BY, Park HB, Shin YJ, Son JI, Ki MR, Oh YW, Bang KN, Choi IS. Epidemiological study on the mumps epidemic: in one primary school in Hwasung-kun, Kyonggi-do. Korean J Epidemiol. 1995; 17:105–115.

16. Kim KH, Ki H, Choi BY, Kim CH, Lee DH, Ko UY, Ki M. Evaluation of mumps vaccine effectiveness by outbreak investigation in one kindergarten in Ulsan City, 2006. Korean J Epidemiol. 2008; 30:110–118.

17. Kim KH, Kim CH, Choi BY, Go UY, Lee DH, Ki M. Mumps transmission control status and inapparent infection rate among middle and high school students during the 2007-2008 mumps outbreaks in Daegu. J Prev Med Public Health. 2009; 42:408–415.

18. Park BC, Cheong HK, Lim HS, Kim DS, Kim D. Epidemiologic investigation of a mumps outbreak in a middle school in Pohang, Korea: effect of vaccination during outbreak. Korean J Epidemiol. 2000; 22:148–158.

19. Kim M, Ki M, Hu Y, Cho B. An epidemiologic investigation on mumps outbreak in Cheju-do, 1998. Korean J Prev Med. 2001; 34:89–99.

20. Korea Centers for Disease Control and Prevention (KCDC). Diseases web statistics system. Accessed 8 February 2015. Available at: http://is.cdc.go.kr/dstat/index.jsp.

21. Whang IS. Results of 2nd MMR entry requirement, 2006-2011. Public Health Wkly Rep. 2011; 4:749–751.

22. Ryu JU, Kim EK, Youn YS, Rhim JW, Lee KY. Outbreaks of mumps: an observational study over two decades in a single hospital in Korea. Korean J Pediatr. 2014; 57:396–402.

23. Ki M, Kim M, Shin YJ, Choi B. MMR Immunization Rate and Related Factors - Findings from Repeated Surveys( 1996, 1999) on Elementary School Students in Kyonggi Province, Korea. J Korean Pediatr Soc. 2001; 44:375–388.

24. Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis. 2012; 206:1542–1548.

25. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Centers for Disease Control and Prevention (CDC). Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013; 62:1–34.

26. Wellington K, Goa KL. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs. 2003; 63:2107–2126.

27. Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Vaccine. 1995; 13:1617–1622.

28. Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks. Clin Infect Dis. 2008; 47:1458–1467.

29. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev. 2012; 2:CD004407.

30. Goh KT. Resurgence of mumps in Singapore caused by the Rubini mumps virus vaccine strain. Lancet. 1999; 354:1355–1356.

31. Montes M, Cilla G, Artieda J, Vicente D, Basterretxea M. Mumps outbreak in vaccinated children in Gipuzkoa (Basque Country), Spain. Epidemiol Infect. 2002; 129:551–556.

32. Choi B, Kim CH, Ki M, Lee SE, Kim CH, Kang C, Yoo HS, Park SK. Development goal and strategy of mumps vaccination program. Seoul, Korea: KCDC;2005.

33. Germann D, Ströhle A, Eggenberger K, Steiner CA, Matter L. An outbreak of mumps in a population partially vaccinated with the Rubini strain. Scand J Infect Dis. 1996; 28:235–238.

34. Goncalves G, De Araujo A, Monteiro Cardoso ML. Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996. Euro Surveill. 1998; 3:119–121.

35. Pons C, Pelayo T, Pachon I, Galmes A, Gonzalez L, Sanchez C, Martinez F. Two outbreaks of mumps in children vaccinated with the Rubini strain in Spain indicate low vaccine efficacy. Euro Surveill. 2000; 5:80–84.

36. Marin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, Lebaron CW. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students--Iowa, 2006. Vaccine. 2008; 26:3601–3607.

37. Cortese MM, Jordan HT, Curns AT, Quinlan PA, Ens KA, Denning PM, Dayan GH. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis. 2008; 46:1172–1180.

38. LeBaron CW, Forghani B, Beck C, Brown C, Bi D, Cossen C, Sullivan BJ. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis. 2009; 199:552–560.

39. Lee JH, Bae GR, Park CS, Chung YS, Kang YA, Han HW, Kang C. Seroprevalence of measles and mumps antibody among preschool children in Korea, according to their vaccination history. Korean J Epidemiol. 2008; 30:34–40.

40. Cortese MM, Barskey AE, Tegtmeier GE, Zhang C, Ngo L, Kyaw MH, Baughman AL, Menitove JE, Hickman CJ, Bellini WJ, Dayan GH, Hansen GR, Rubin S. Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity. J Infect Dis. 2011; 204:1413–1422.

41. Vandermeulen C, Roelants M, Vermoere M, Roseeuw K, Goubau P, Hoppenbrouwers K. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine. 2004; 22:2713–2716.

42. Scherer A, McLean A. Mathematical models of vaccination. Br Med Bull. 2002; 62:187–199.

43. Barskey AE, Schulte C, Rosen JB, Handschur EF, Rausch-Phung E, Doll MK, Cummings KP, Alleyne EO, High P, Lawler J, Apostolou A, Blog D, Zimmerman CM, Montana B, Harpaz R, Hickman CJ, Rota PA, Rota JS, Bellini WJ, Gallagher KM. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med. 2012; 367:1704–1713.

44. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008; 47:401–409.

45. Kutty PK, McLean HQ, Lawler J, Schulte C, Hudson JM, Blog D, Wallace G. Risk factors for transmission of mumps in a highly vaccinated population in Orange County, NY, 2009-2010. Pediatr Infect Dis J. 2014; 33:121–125.

46. Park O. Reemerging mumps and measles in ROK. Annual update symposium on infectious diseases, 2014. Seoul, Korea: Korean Society of Infectious Diseases;p. 170–193.

47. Plotkin SA. Commentary: Mumps vaccines: do we need a new one? Pediatr Infect Dis J. 2013; 32:381–382.

48. Santos CL, Ishida MA, Foster PG, Sallum MA, Benega MA, Borges DB, Corrêa KO, Constantino CR, Afzal MA, Paiva TM. Detection of a new mumps virus genotype during parotitis epidemic of 2006-2007 in the state of Sao Paulo, Brazil. J Med Virol. 2008; 80:323–329.

49. Jin L, Orvell C, Myers R, Rota PA, Nakayama T, Forcic D, Hiebert J, Brown KE. Genomic diversity of mumps virus and global distribution of the 12 genotypes. Rev Med Virol. 2015; 25:85–101.

50. Rubin SA, Qi L, Audet SA, Sullivan B, Carbone KM, Bellini WJ, Rota PA, Sirota L, Beeler J. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis. 2008; 198:508–515.

51. Kim ST. Genotype analysis of Mumps isolates in Korea, 2010. Public Health Wkly Rep. 2012; 5:21–24.

52. Rubin S, Mauldin J, Chumakov K, Vanderzanden J, Iskow R, Carbone K. Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains. Vaccine. 2006; 24:2662–2668.

53. Rubin SA, Link MA, Sauder CJ, Zhang C, Ngo L, Rima BK, Duprex WP. Recent mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol. 2012; 86:615–620.

54. Ki M. Evaluation of mumps outbreak and serology. Seoul, Korea: KCDC;2009.

55. Kaaijk P, van der Zeijst B, Boog M, Hoitink C. Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype. Euro Surveill. 2008; 13:pii: 18914.

56. Hatchette TF, Mahony JB, Chong S, LeBlanc JJ. Difficulty with mumps diagnosis: what is the contribution of mumps mimickers? J Clin Virol. 2009; 46:381–383.

57. Barskey AE, Juieng P, Whitaker BL, Erdman DD, Oberste MS, Chern SW, Schmid DS, Radford KW, McNall RJ, Rota PA, Hickman CJ, Bellini WJ, Wallace GS. Viruses detected among sporadic cases of parotitis, United States, 2009-2011. J Infect Dis. 2013; 208:1979–1986.

58. Bitsko RH, Cortese MM, Dayan GH, Rota PA, Lowe L, Iversen SC, Bellini WJ. Detection of RNA of mumps virus during an outbreak in a population with a high level of measles, mumps, and rubella vaccine coverage. J Clin Microbiol. 2008; 46:1101–1103.

59. Fiebelkorn AP, Barskey AE, Hickman C, Bellini WJ. Mumps. In : . Manual for the surveillance of vaccine-preventable diseases. 5th ed. Atlanta, GA: CDC;2012.

60. Rota JS, Turner JC, Yost-Daljev MK, Freeman M, Toney DM, Meisel E, Williams N, Sowers SB, Lowe L, Rota PA, Nicolai LA, Peake L, Bellini WJ. Investigation of a mumps outbreak among university students with two measles-mumps-rubella (MMR) vaccinations, Virginia, September-December 2006. J Med Virol. 2009; 81:1819–1825.

61. Sanz JC, Mosquera Mdel M, Echevarría JE, Fernández M, Herranz N, Palacios G, De Ory F. Sensitivity and specificity of immunoglobulin G titer for the diagnosis of mumps virus in infected patients depending on vaccination status. APMIS. 2006; 114:788–794.

62. Borgmann S, Schwab F, Santibanez S, Mankertz A. Mumps virus infection in vaccinated patients can be detected by an increase in specific IgG antibodies to high titres: a retrospective study. Epidemiol Infect. 2014; 142:2388–2396.

63. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008; 197:950–956.

64. Sakata H, Tsurudome M, Hishiyama M, Ito Y, Sugiura A. Enzyme-linked immunosorbent assay for mumps IgM antibody: comparison of IgM capture and indirect IgM assay. J Virol Methods. 1985; 12:303–311.

65. Latner DR, McGrew M, Williams N, Lowe L, Werman R, Warnock E, Gallagher K, Doyle P, Smole S, Lett S, Cocoros N, DeMaria A, Konomi R, Brown CJ, Rota PA, Bellini WJ, Hickman CJ. Enzyme-linked immunospot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis. Clin Vaccine Immunol. 2011; 18:35–42.

66. Yung CF, Andrews N, Bukasa A, Brown KE, Ramsay M. Mumps complications and effects of mumps vaccination, England and Wales, 2002-2006. Emerg Infect Dis. 2011; 17:661–667. quiz 766.

67. National Institute of Infectious Diseases. Mumps (infectious parotitis) in Japan, as of July 2013. IASR. 2013; 34:219–220.

68. Nelson GE, Aguon A, Valencia E, Oliva R, Guerrero ML, Reyes R, Lizama A, Diras D, Mathew A, Camacho EJ, Monforte MN, Chen TH, Mahamud A, Kutty PK, Hickman C, Bellini WJ, Seward JF, Gallagher K, Fiebelkorn AP. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010. Pediatr Infect Dis J. 2013; 32:374–380.

69. Ogbuanu IU, Kutty PK, Hudson JM, Blog D, Abedi GR, Goodell S, Lawler J, McLean HQ, Pollock L, Rausch-Phung E, Schulte C, Valure B, Armstrong GL, Gallagher K. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics. 2012; 130:e1567–e1574.

70. Latner DR, McGrew M, Williams NJ, Sowers SB, Bellini WJ, Hickman CJ. Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method. Clin Vaccine Immunol. 2014; 21:286–297.